Nuvectis Pharma, Inc. 8-K

What Happened

• Nuvectis Pharma, Inc. (NASDAQ: NVCT) filed an 8-K reporting the results of its 2026 Annual Meeting held June 11, 2026 via an online platform. Stockholders representing 16,193,686 shares (60.8% of outstanding) were present in person or by proxy, establishing a quorum.
• The company corrected an earlier error in its proxy: the Proxy filed April 27, 2026 misstated shares outstanding as 27,668,036; the correct number as of the April 13, 2026 record date is 26,614,628. The filing states this correction does not affect the validity or outcome of any votes.
• All proposals at the meeting were approved. Class I director Ron Bentsur was elected to hold office until the 2029 annual meeting, and Kesselman & Kesselman was ratified as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Shares outstanding (corrected): 26,614,628 as of April 13, 2026 (Proxy had incorrectly listed 27,668,036).
• Meeting quorum: 16,193,686 shares represented, equal to 60.8% of outstanding shares.
• Director election vote (Ron Bentsur): For 8,354,838; Against 391,265; Abstentions/Withheld 216; Broker non-votes 7,447,367.
• Auditor ratification vote (Kesselman & Kesselman): For 15,662,222; Against 10,574; Abstentions/Withheld 520,890.

Why It Matters

• The election of Ron Bentsur and ratification of the auditor are governance outcomes that investors watch for board continuity and oversight of financial reporting.
• The corrected shares-outstanding figure clarifies voting math and ownership percentages; the company confirms the correction did not change vote results or invalidate the meeting.
• Ratifying the auditor finalizes the firm responsible for auditing the company’s 2026 financial statements, an item relevant to financial transparency and investor confidence.